This is a 12-week, intent-to-treat, randomized controlled trial to evaluate the impact of N-Acetylcysteine (NAC) versus matched placebo (PBO) twice daily, added to compliance enhancement (CE) and contingency management (CM) interventions, on cannabis use among treatment-seeking adults.  The primary analysis will evaluate the impact of NAC versus PBO on cannabis use during the 12-week treatment intervention with the primary outcome measure being the proportion of negative urine cannabinoid tests submitted during active treatment, compared between the two treatment groups.

CTN Protocol ID: 
Enrollment Status: 
Completed ID: 

Principal Investigator(s): 

Kevin Gray, M.D.
Associate Professor
Medical University of South Carolina
125 Doughty Street, MSC861
Charleston, SC 29455

Participating Sites